Science

Pipeline

 

Inhaled AAT

  •  
  • Phase I
  • Phase II
  • Phase III
Phase 3

Therapeutic Area: AAT Deficiency

The InnovAATe Study is a Prospective Phase III Multi-center, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of “Kamada-AAT for Inhalation” in Adult Patients with Alpha-1 Antitrypsin Deficiency, followed by an Open-Label Extension.

Visit innovaate-study.com to learn more about the study.

CMV Immune Globulin

  •  
  • Phase I
  • Phase II
  • Phase III
Post Marketing

Therapeutic Area: CMV Disease

CYTOGAM is the only plasma-derived IgG approved in the U.S. and Canada for prophylaxis of CMV disease after Solid Organ Transplantation. CMV is the leading cause of organ rejection post-transplant.

 

Plasma Eye Drops

  •  
  • Phase I
  • Phase II
  • Phase III
Pre Clinical

Therapeutic Area: Ocular Diseases

Human plasma-based eye drops for potential treatment of several ocular conditions.

Kamada is at the forefront of clinical research for plasma-derived proteins and additional therapeutic indications for Alpha-1 Antitrypsin (AAT).